Holen Sie sich die Stockscreener-App
2.72
1.87%
0.05
Handel nachbörslich:
2.75
0.03
+1.10%
C 4 Therapeutics Inc Aktie (CCCC) Neueste Nachrichten
Is C4 Therapeutics Inc. forming a bottoming baseDollar Strength & AI Enhanced Execution Alerts - Newser
Can C4 Therapeutics Inc. recover in the next quarterEarnings Recap Summary & AI Driven Stock Movement Reports - Newser
Historical volatility pattern of C4 Therapeutics Inc. visualizedJuly 2025 Selloffs & AI Enhanced Trading Alerts - Newser
Machine Learning Models Forecast C4 Therapeutics Inc. UptickPortfolio Growth Summary & Daily Stock Momentum Reports - beatles.ru
Will C4 Therapeutics Inc. benefit from seasonalityWeekly Trading Summary & Daily Volume Surge Signals - خودرو بانک
What is C4 Therapeutics Inc.’s book value per shareEarnings Recap Report & Precise Trade Entry Recommendations - خودرو بانک
What is the dividend yield of C4 Therapeutics Inc.July 2025 Summary & Safe Entry Point Identification - خودرو بانک
Can C4 Therapeutics Inc. sustain its profitability2025 Trading Volume Trends & Verified Stock Trade Ideas - خودرو بانک
Can C4 Therapeutics Inc. weather a recessionQuarterly Risk Review & Weekly High Return Forecasts - خودرو بانک
Vera Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Syndax Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Biogen’s IND for BIIB-142 accepted by FDA - BioWorld MedTech
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics, Inc. (NASDAQ:CCCC) Held Back By Insufficient Growth Even After Shares Climb 33% - simplywall.st
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Chart overlay techniques for tracking C4 Therapeutics Inc.Trade Volume Report & Short-Term Trading Opportunity Alerts - Newser
Real time breakdown of C4 Therapeutics Inc. stock performanceQuarterly Market Review & Verified Technical Trade Signals - Newser
Visual trend scoring systems applied to C4 Therapeutics Inc.July 2025 Sector Moves & Growth Focused Entry Reports - Newser
How to integrate C4 Therapeutics Inc. into portfolio analysis toolsJuly 2025 Gainers & Comprehensive Market Scan Reports - Newser
Does C4 Therapeutics Inc. show high probability of reboundJuly 2025 Levels & Accurate Intraday Trading Signals - Newser
Building trade automation scripts for C4 Therapeutics Inc.2025 Performance Recap & Comprehensive Market Scan Insights - Newser
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Biogen Inc. shares fall 2.38% intraday as C4 Therapeutics highlights recent achievements in Biogen. - AInvest
C4 Therapeutics (CCCC) Receives Buy Rating from Guggenheim | CCC - GuruFocus
Why is C4 Therapeutics Inc. stock going downJuly 2025 Price Swings & Low Risk High Reward Trade Ideas - خودرو بانک
C4 Therapeutics shares rise 1.95% premarket after Biogen's IND application for IRAK4 degrader accepted by FDA. - AInvest
Biogen's IND Application Accepted by FDA for C4 Therapeutics' Treatment of Autoimmune Diseases - AInvest
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration - GlobeNewswire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics stock initiated with Buy rating at Guggenheim on myeloma drug potential - Investing.com
What the charts say about C4 Therapeutics Inc. todayJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - Newser
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2025 - biospace.com
How hedge fund analytics apply to C4 Therapeutics Inc. stockStop Loss & Short-Term High Return Strategies - Newser
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Astria Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Viridian Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics to Present Updated Data on Cemsidomide for Multiple Myeloma at IMS Annual Meeting 2025 - Quiver Quantitative
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting - The Manila Times
C4 Therapeutics to Present Data from the Phase 1 Trial of - GlobeNewswire
Novel Multiple Myeloma Drug Trial Results: C4 Therapeutics' Cemsidomide Shows Promise in Phase 1 Study - Stock Titan
How moving averages guide C4 Therapeutics Inc. trading2025 Winners & Losers & High Accuracy Investment Entry Signals - Newser
Is C4 Therapeutics Inc. on track to beat earningsJuly 2025 Sentiment & Fast Entry High Yield Tips - خودرو بانک
Detecting support and resistance levels for C4 Therapeutics Inc.2025 Analyst Calls & AI Enhanced Trade Execution Alerts - Newser
Best data tools to analyze C4 Therapeutics Inc. stockJuly 2025 Spike Watch & Weekly Market Pulse Alerts - Newser
Protara Therapeutics’ Equity Inducement Grants: A Strategic Catalyst for Talent Retention and Long-Term Value Creation - AInvest
Entrada Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Protara Therapeutics, Inc. reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Karyopharm Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Akebia Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Biotech Firm Protara Therapeutics Issues $3.17/Share Stock Options in Key Employee Compensation Plan - Stock Titan
Identifying reversal signals in C4 Therapeutics Inc.Chart Signals & Safe Capital Investment Plans - Newser
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):